Sarepta Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
million ) and guided 2026 approved-therapy revenue to roughly $1.2 billion to $1.4 billion , while ending 2025 with $954 million in cash and expecting unit-volume margins in the high-70% range after material cost-of-sales adjustments. Management said 2026 is a commercial “ critical reset ” for ELEVIDYS after two tragic 2025 events, with updated labeling, expanded outreach, and early signs of renewed site engagement; clinically, EMBARK three-year toplines showed a statistically significant 4.39-point NSAA benefit and ~ 70–73% slowing on key functional measures, and a sirolimus pretreatment Cohort 8 in non-ambulatory patients is underway with data expected by end-2026. CEO Doug Ingram plans to retire around the end of 2026 and the board has launched a comprehensive successor search, while the pipeline advances include planned proof-of-concept readouts for DM1 and FSHD siRNA programs by end-Q1 and initiation of a Huntington's trial with first dosing expected in H1 2026. Interested
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics (SRPT) was given a new $25.00 price target by Loop Capital.MarketBeat
- Sarepta Therapeutics (SRPT) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Sarepta Therapeutics (SRPT) had its price target lowered by Wedbush from $34.00 to $29.00. They now have an "outperform" rating on the stock.MarketBeat
- Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SRPT's page on the SEC website